Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert W Harrison

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Biochemical and Biophysical Research Communications|September 28, 2020
Machine learning methods accurately predict host specificity of coronaviruses based on spike sequences aloneKiril Kuzmin, Ayotomiwa Ezekiel Adeniyi, Arthur Kevin DaSouza, et al.
Journal of Medicinal Chemistry|February 17, 2006
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90MAndrey Yu Kovalevsky, Yunfeng Tie, Fengling Liu, et al.
Journal of Medicinal Chemistry|March 10, 2012
Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ringYu-Chung E Chang, XiaXia Yu, Ying Zhang, et al.
Protein Science : a Publication of the Protein Society|January 13, 2012
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitorsYunfeng Tie, Yuan-Fang Wang, Peter I Boross, et al.
Journal of Medicinal Chemistry|January 10, 2013
Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 proteaseHongmei Zhang, Yuan-Fang Wang, Chen-Hsiang Shen, et al.
European Journal of Biochemistry|August 16, 2002
Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sitesAnita Fehér, Irene T Weber, Péter Bagossi, et al.
Journal of Molecular Biology|April 7, 2004
High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strainsYunfeng Tie, Peter I Boross, Yuan-Fang Wang, et al.
Circulation Research|May 24, 2003
Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthasesShakil A Khan, Michel W Skaf, Robert W Harrison, et al.
American Heart Journal|November 7, 2015
A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trialSunil V Rao, Uwe Zeymer, Pamela S Douglas, et al.
American Heart Journal|March 31, 2015
Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) studyWei Jiang, Stephen H Boyle, Thomas L Ortel, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Biochemical and Biophysical Research Communications|September 28, 2020
Machine learning methods accurately predict host specificity of coronaviruses based on spike sequences aloneKiril Kuzmin, Ayotomiwa Ezekiel Adeniyi, Arthur Kevin DaSouza, et al.
Journal of Medicinal Chemistry|February 17, 2006
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90MAndrey Yu Kovalevsky, Yunfeng Tie, Fengling Liu, et al.
Journal of Medicinal Chemistry|March 10, 2012
Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ringYu-Chung E Chang, XiaXia Yu, Ying Zhang, et al.
Protein Science : a Publication of the Protein Society|January 13, 2012
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitorsYunfeng Tie, Yuan-Fang Wang, Peter I Boross, et al.
Journal of Medicinal Chemistry|January 10, 2013
Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 proteaseHongmei Zhang, Yuan-Fang Wang, Chen-Hsiang Shen, et al.
European Journal of Biochemistry|August 16, 2002
Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sitesAnita Fehér, Irene T Weber, Péter Bagossi, et al.
Journal of Molecular Biology|April 7, 2004
High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strainsYunfeng Tie, Peter I Boross, Yuan-Fang Wang, et al.
Circulation Research|May 24, 2003
Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthasesShakil A Khan, Michel W Skaf, Robert W Harrison, et al.
American Heart Journal|November 7, 2015
A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trialSunil V Rao, Uwe Zeymer, Pamela S Douglas, et al.
American Heart Journal|March 31, 2015
Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) studyWei Jiang, Stephen H Boyle, Thomas L Ortel, et al.
Pageof 11